PMID- 21737656
OWN - NLM
STAT- MEDLINE
DCOM- 20111019
LR  - 20220409
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 31
IP  - 6
DP  - 2011 Jun
TI  - Identification of polymorphisms associated with hypertriglyceridemia and 
      prolonged survival induced by bexarotene in treating non-small cell lung cancer.
PG  - 2303-11
AB  - BACKGROUND: Bexarotene was evaluated in treating advanced non small cell lung 
      cancer (NSCLC) in two phase III trials. Although a significant survival benefit 
      was not observed for the overall bexarotene-treated population (617 patients), a 
      third of bexarotene-treated patients who developed high-grade 
      hypertriglyceridemia exhibited significantly longer survival. PATIENTS AND 
      METHODS: In order to identify genomic polymorphisms that could serve as potential 
      predictive biomarkers for response and improved survival in NSCLC patients, DNA 
      samples extracted from plasma archived from 403 patients were genotyped using 
      Affymetrix 500K whole genome SNP arrays and/or Sequenom iPLEX assays. RESULTS: 
      Fourteen SNPs were identified on nine loci that showed significant associations 
      with high-grade hypertriglyceridemia induced by bexarotene. Four such single 
      nucleotide polymorphisms (SNPs) reside on the region upstream of solute carrier 
      family 10, member 2 (SLC10A2), and one SNP is located close to lymphocyte 
      cytosolic protein 1 (LCP1), whose expression correlated with the activity of 
      bexarotene in tumor cells. CONCLUSION: We identified novel polymorphisms 
      exhibiting significant association with bexarotene induced hypertriglyceridemia, 
      implicating their potential in predicting bexarotene-improved survival response.
FAU - Luo, Wen
AU  - Luo W
AD  - Ligand Pharmaceuticals, 5003 Ruette De Mer, San Diego, CA 92130, USA. 
      WenL888@hotmail.com
FAU - Schork, Nicholas J
AU  - Schork NJ
FAU - Marschke, Keith B
AU  - Marschke KB
FAU - Ng, Shi-Chung
AU  - Ng SC
FAU - Hermann, Thomas W
AU  - Hermann TW
FAU - Zhang, Jinkun
AU  - Zhang J
FAU - Sanders, Jennifer M
AU  - Sanders JM
FAU - Tooker, Patricia
AU  - Tooker P
FAU - Malo, Nathalie
AU  - Malo N
FAU - Zapala, Matthew A
AU  - Zapala MA
FAU - Dziewanowska, Zofia E
AU  - Dziewanowska ZE
FAU - Negro-Vilar, Andres
AU  - Negro-Vilar A
FAU - Meglasson, Martin D
AU  - Meglasson MD
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Tetrahydronaphthalenes)
RN  - 9007-49-2 (DNA)
RN  - A61RXM4375 (Bexarotene)
SB  - IM
MH  - Bexarotene
MH  - Carcinoma, Non-Small-Cell Lung/*blood/drug therapy/genetics
MH  - Case-Control Studies
MH  - Clinical Trials, Phase III as Topic
MH  - DNA/blood/genetics
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Hypertriglyceridemia/blood/*chemically induced/*genetics
MH  - Lung Neoplasms/*blood/drug therapy/genetics
MH  - Male
MH  - Middle Aged
MH  - Polymorphism, Single Nucleotide
MH  - Tetrahydronaphthalenes/*adverse effects/therapeutic use
EDAT- 2011/07/09 06:00
MHDA- 2011/10/20 06:00
CRDT- 2011/07/09 06:00
PHST- 2011/07/09 06:00 [entrez]
PHST- 2011/07/09 06:00 [pubmed]
PHST- 2011/10/20 06:00 [medline]
AID - 31/6/2303 [pii]
PST - ppublish
SO  - Anticancer Res. 2011 Jun;31(6):2303-11.